Intellia Therapeutics (NTLA) shares were down 5% in early Thursday trading after it reported Q3 revenue that fell year on year and missed analyst estimates.
The company a reported Q3 net loss Thursday of $0.91 per diluted share, narrower than a loss of $0.92 a year earlier.
Analysts polled by FactSet expected a loss of $0.80.
Revenue for the quarter ended Sept. 30 was $7.2 million, down from $13.8 million a year earlier.
Analysts expected $9.7 million.
Price: 11.56, Change: -0.76, Percent Change: -6.13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments